These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8314932)

  • 1. Confirmation of a dopamine metabolite in parkinsonian brain tissue by gas chromatography-mass spectrometry.
    Mattammal MB; Chung HD; Strong R; Hsu FF
    J Chromatogr; 1993 May; 614(2):205-12. PubMed ID: 8314932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography.
    Burke WJ; Chung HD; Li SW
    Anal Biochem; 1999 Aug; 273(1):111-6. PubMed ID: 10452806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechols in post-mortem brain of patients with Parkinson disease.
    Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Basile MJ; Mash DC
    Eur J Neurol; 2011 May; 18(5):703-10. PubMed ID: 21073636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
    Burke WJ; Li SW; Williams EA; Nonneman R; Zahm DS
    Brain Res; 2003 Nov; 989(2):205-13. PubMed ID: 14556942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
    Jinsmaa Y; Isonaka R; Sharabi Y; Goldstein DS
    J Pharmacol Exp Ther; 2020 Feb; 372(2):157-165. PubMed ID: 31744850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of monoamine oxidase gene knockout on dopamine metabolism in mouse brain structures.
    Popova NK; Gilinskii MA; Amstislavskaya TG
    Bull Exp Biol Med; 2004 Apr; 137(4):382-4. PubMed ID: 15452609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.
    Li SW; Lin TS; Minteer S; Burke WJ
    Brain Res Mol Brain Res; 2001 Sep; 93(1):1-7. PubMed ID: 11532332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
    Kristal BS; Conway AD; Brown AM; Jain JC; Ulluci PA; Li SW; Burke WJ
    Free Radic Biol Med; 2001 Apr; 30(8):924-31. PubMed ID: 11295535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reactive oxygen species and 3,4-dihydroxyphenylacetaldehyde in pathogenesis of Parkinson disease].
    Rybakowska I; Szreder G; Kaletha K; Barwina M; Waldman W; Sein Anand J
    Przegl Lek; 2011; 68(8):486-7. PubMed ID: 22010445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone.
    Anderson DG; Mariappan SV; Buettner GR; Doorn JA
    J Biol Chem; 2011 Jul; 286(30):26978-86. PubMed ID: 21642436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and determination of 3,4-dihydroxyphenylacetaldehyde, the dopamine metabolite in in vivo dialysate from rat striatum.
    Colzi A; Musolino A; Iuliano A; Fornai F; Bonuccelli U; Corsini GU
    J Neurochem; 1996 Apr; 66(4):1510-7. PubMed ID: 8627306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
    Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH
    Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The coaction of tonic and phasic dopamine dynamics.
    Atcherley CW; Wood KM; Parent KL; Hashemi P; Heien ML
    Chem Commun (Camb); 2015 Feb; 51(12):2235-8. PubMed ID: 25249291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.
    Vanle BC; Florang VR; Murry DJ; Aguirre AL; Doorn JA
    Biochem Biophys Res Commun; 2017 Oct; 492(2):275-281. PubMed ID: 28830811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative metabolite of dopamine, 3,4-dihydroxyphenylacetaldehyde, induces dopamine release from PC12 cells by a Ca2+-independent mechanism.
    Hashimoto T; Yabe-Nishimura C
    Brain Res; 2002 Mar; 931(1):96-9. PubMed ID: 11897094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of monoamine oxidase B activity by high-performance liquid chromatography with electrochemical detection.
    Husseini H; Mitrovic V; Schlepper M
    J Chromatogr B Biomed Appl; 1995 Oct; 672(1):138-42. PubMed ID: 8590926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of capillary gas chromatography/mass spectrometry for the determination of acidic dopamine metabolites in human brain.
    Michotte Y; Deleu D; Ebinger G
    Biomed Mass Spectrom; 1985 Dec; 12(12):704-6. PubMed ID: 2936400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Youngster SK; Sonsalla PK; Heikkila RE
    J Neurochem; 1987 Mar; 48(3):929-34. PubMed ID: 3492590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.